Form 4: Adaptive Bio COO Sells Shares After Option Exercise

Adaptive Biotechnologies' President and COO, Julie Rubinstein, executed a series of planned stock option exercises and subsequent sales of common stock in mid-March 2026.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (ADPT), reported transactions involving the company's common stock.
• The transactions occurred on March 16, 17, and 18, 2026, and were conducted under a Rule 10b5-1 trading plan adopted on November 18, 2025.
• On each of these three days, Rubinstein acquired 14,722 shares of common stock by exercising fully vested stock options at a price of $6.55 per share.
• Concurrently, on each of the same three days, Rubinstein disposed of 19,060 shares of common stock.
• The sale prices were weighted averages: $13.41 on March 16, $13.40 on March 17, and $13.18 on March 18, 2026.
• Following these transactions, Rubinstein's direct beneficial ownership of common stock decreased from 522,656 shares before the first sale to 494,920 shares after the last reported transaction.
• The number of beneficially owned stock options decreased from 48,105 to 18,661 after the exercises.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative event. While the transactions were planned under Rule 10b5-1, mitigating concerns of opportunistic selling, the net reduction in a key executive's direct ownership could still be interpreted with slight caution by some investors.

Positives

• The executive realized significant value by exercising stock options at $6.55 per share and selling the acquired shares at prices ranging from $13.18 to $13.41, indicating a substantial profit.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to personal financial management rather than a reaction to immediate company news.

Negatives

• The net effect of the transactions was a reduction in the direct beneficial ownership of common stock by a key executive, Julie Rubinstein, by 27,736 shares over three days.
• Insider selling, even when planned, can sometimes be perceived negatively by investors as it reduces the executive's direct equity stake in the company.

Risks

• While executed under a 10b5-1 plan, the consistent selling by a high-ranking executive could be interpreted by some investors as a lack of strong conviction in the company's near-term stock price appreciation, potentially impacting investor sentiment.

Future Outlook

Not applicable to this filing type, as Form 4 reports historical insider transactions.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by the market. While sales under a Rule 10b5-1 plan are pre-scheduled and often for personal financial planning, a consistent pattern of selling by a high-level executive like a COO can still influence investor perception regarding the company's near-term growth prospects or valuation relative to peers in the biotechnology sector.

Stakeholder Impact

• Shareholders may interpret the net reduction in direct beneficial ownership by a key executive as a signal, potentially influencing their investment decisions.
• The transactions demonstrate the executive's realization of value from their compensation package, which is a standard aspect of executive remuneration.

Key Dates

Recommendation

While insider selling, even under a 10b5-1 plan, can sometimes be a yellow flag, this Form 4 alone does not provide sufficient information to warrant a strong 'buy' or 'sell' recommendation. The planned nature of the sales suggests personal financial management rather than a bearish outlook on the company. Investors should 'hold' and consider these transactions in the broader context of Adaptive Biotechnologies' financial performance, strategic initiatives, and overall market conditions.

Keywords

ADPT, Adaptive Biotechnologies, Julie Rubinstein, Insider Trading, Form 4, Stock Options, Stock Sale, 10b5-1 Plan, Executive Compensation